Table of Contents Author Guidelines Submit a Manuscript
International Journal of Endocrinology
Volume 2017 (2017), Article ID 5076732, 12 pages
https://doi.org/10.1155/2017/5076732
Review Article

Latent Inflammation and Insulin Resistance in Adipose Tissue

1Russian Cardiology Research and Production Centre, Moscow 121552, Russia
2Faculty of Basic Medicine, M.V. Lomonosov Moscow State University, Moscow 119192, Russia
3M.V. Lomonosov Moscow State University Medical Center, Moscow 119192, Russia
4Endocrinology Research Centre, Moscow 117031, Russia

Correspondence should be addressed to I. S. Stafeev

Received 3 May 2017; Accepted 17 July 2017; Published 17 August 2017

Academic Editor: Claudio Casella

Copyright © 2017 I. S. Stafeev et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. WHO, World Health Statistics 2015, 2015.
  2. R. Levine, M. S. Goldstein, B. Huddlestun, and S. P. Klein, “Action of insulin on the ‘permeability’ of cells to free hexoses, as studied by its effect on the distribution of galactose,” The American Journal of Physiology, vol. 163, no. 1, pp. 70–76, 1950. View at Google Scholar
  3. G. Wilcox, “Insulin and insulin resistance,” The Clinical Biochemist Reviews/Australian Association of Clinical Biochemists, vol. 26, no. 2, pp. 19–39, 2005. View at Google Scholar
  4. E. Zelzer, Y. Levy, C. Kahana, B. Z. Shilo, M. Rubinstein, and B. Cohen, “Insulin induces transcription of target genes through the hypoxia-inducible factor HIF-1alpha/ARNT,” The EMBO Journal, vol. 17, no. 17, pp. 5085–5094, 1998. View at Publisher · View at Google Scholar · View at Scopus
  5. V. T. Samuel, K. F. Petersen, and G. I. Shulman, “Lipid-induced insulin resistance: unravelling the mechanism,” Lancet (London, England), vol. 375, no. 9733, pp. 2267–2277, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. N. Kumashiro, D. M. Erion, D. Zhang et al., “Cellular mechanism of insulin resistance in nonalcoholic fatty liver disease,” Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 39, pp. 16381–16385, 2011. View at Publisher · View at Google Scholar · View at Scopus
  7. S. M. Choi, D. F. Tucker, D. N. Gross et al., “Insulin regulates adipocyte lipolysis via an Akt-independent signaling pathway,” Molecular and Cellular Biology, vol. 30, no. 21, pp. 5009–5020, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. A. R. Saltiel and C. R. Kahn, “Insulin signalling and the regulation of glucose and lipid metabolism,” Nature, vol. 414, no. 6865, pp. 799–806, 2001. View at Publisher · View at Google Scholar · View at Scopus
  9. M. Bluher, M. D. Michael, O. D. Peroni et al., “Adipose tissue selective insulin receptor knockout protects against obesity and obesity-related glucose intolerance,” Developmental Cell, vol. 3, no. 1, pp. 25–38, 2002. View at Google Scholar
  10. M. Sakaguchi, S. Fujisaka, W. Cai et al., “Adipocyte dynamics and reversible metabolic syndrome in mice with an inducible adipocyte-specific deletion of the insulin receptor,” Cell Metabolism, vol. 25, no. 2, pp. 448–462, 2017. View at Publisher · View at Google Scholar
  11. K. Siddle, “Signalling by insulin and IGF receptors: supporting acts and new players,” Journal of Molecular Endocrinology, vol. 47, no. 1, pp. R1–R10, 2011. View at Publisher · View at Google Scholar · View at Scopus
  12. J. Boucher, S. Softic, A. El Ouaamari et al., “Differential roles of insulin and IGF-1 receptors in adipose tissue development and function,” Diabetes, vol. 65, no. 8, pp. 2201–2213, 2016. View at Publisher · View at Google Scholar · View at Scopus
  13. Y. Kido, J. Nakae, and D. Accili, “Clinical review 125: the insulin receptor and its cellular targets,” The Journal of Clinical Endocrinology and Metabolism, vol. 86, no. 3, pp. 972–979, 2001. View at Publisher · View at Google Scholar
  14. L. M. Shaw, “The insulin receptor substrate (IRS) proteins: at the intersection of metabolism and cancer,” Cell Cycle (Georgetown, Texas), vol. 10, no. 11, pp. 1750–1756, 2011. View at Publisher · View at Google Scholar · View at Scopus
  15. J. Boucher, A. Kleinridders, and C. R. Kahn, “Insulin receptor signaling in normal and insulin-resistant states,” Cold Spring Harbor Perspectives in Biology, vol. 6, no. 1, 2014. View at Publisher · View at Google Scholar · View at Scopus
  16. X. J. Sun, D. L. Crimmins, M. G. Myers Jr., M. Miralpeix, and M. F. White, “Pleiotropic insulin signals are engaged by multisite phosphorylation of IRS-1,” Molecular and Cellular Biology, vol. 13, no. 12, pp. 7418–7428, 1993. View at Google Scholar
  17. E. Araki, M. A. Lipes, M. E. Patti et al., “Alternative pathway of insulin signalling in mice with targeted disruption of the IRS-1 gene,” Nature, vol. 372, no. 6502, pp. 186–190, 1994. View at Publisher · View at Google Scholar · View at Scopus
  18. D. J. Withers, J. S. Gutierrez, H. Towery et al., “Disruption of IRS-2 causes type 2 diabetes in mice,” Nature, vol. 391, no. 6670, pp. 900–904, 1998. View at Publisher · View at Google Scholar · View at Scopus
  19. S. Sciacchitano and S. I. Taylor, “Cloning, tissue expression, and chromosomal localization of the mouse IRS-3 gene,” Endocrinology, vol. 138, no. 11, pp. 4931–4940, 1997. View at Publisher · View at Google Scholar
  20. M. Bjornholm, A. R. He, A. Attersand et al., “Absence of functional insulin receptor substrate-3 (IRS-3) gene in humans,” Diabetologia, vol. 45, no. 12, pp. 1697–1702, 2002. View at Publisher · View at Google Scholar · View at Scopus
  21. V. R. Fantin, B. E. Lavan, Q. Wang et al., “Cloning, tissue expression, and chromosomal location of the mouse insulin receptor substrate 4 gene,” Endocrinology, vol. 140, no. 3, pp. 1329–1337, 1999. View at Publisher · View at Google Scholar
  22. V. R. Fantin, Q. Wang, G. E. Lienhard, and S. R. Keller, “Mice lacking insulin receptor substrate 4 exhibit mild defects in growth, reproduction, and glucose homeostasis,” American Journal of Physiology Endocrinology and Metabolism, vol. 278, no. 1, pp. E127–E133, 2000. View at Google Scholar
  23. D. Cai, S. Dhe-Paganon, P. A. Melendez, J. Lee, and S. E. Shoelson, “Two new substrates in insulin signaling, IRS5/DOK4 and IRS6/DOK5,” The Journal of Biological Chemistry, vol. 278, no. 28, pp. 25323–25330, 2003. View at Publisher · View at Google Scholar · View at Scopus
  24. R. B. Birge, C. Kalodimos, F. Inagaki, and S. Tanaka, “Crk and CrkL adaptor proteins: networks for physiological and pathological signaling,” Cell Communication and Signaling, vol. 7, p. 13, 2009. View at Publisher · View at Google Scholar · View at Scopus
  25. P. T. Hawkins, K. E. Anderson, K. Davidson, and L. R. Stephens, “Signalling through class I PI3Ks in mammalian cells,” Biochemical Society Transactions, vol. 34, Part 5, pp. 647–662, 2006. View at Publisher · View at Google Scholar · View at Scopus
  26. L. R. Pearce, D. Komander, and D. R. Alessi, “The nuts and bolts of AGC protein kinases,” Nature Reviews Molecular Cell Biology, vol. 11, no. 1, pp. 9–22, 2010. View at Publisher · View at Google Scholar · View at Scopus
  27. D. R. Alessi, S. R. James, C. P. Downes et al., “Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Balpha,” Current Biology, vol. 7, no. 4, pp. 261–269, 1997. View at Google Scholar
  28. A. Mora, D. Komander, D. M. van Aalten, and D. R. Alessi, “PDK1, the master regulator of AGC kinase signal transduction,” Seminars in Cell & Developmental Biology, vol. 15, no. 2, pp. 161–170, 2004. View at Google Scholar
  29. M. Frodin, T. L. Antal, B. A. Dummler et al., “A phosphoserine/threonine-binding pocket in AGC kinases and PDK1 mediates activation by hydrophobic motif phosphorylation,” The EMBO Journal, vol. 21, no. 20, pp. 5396–5407, 2002. View at Google Scholar
  30. P. T. Bhaskar and N. Hay, “The two TORCs and Akt,” Developmental Cell, vol. 12, no. 4, pp. 487–502, 2007. View at Publisher · View at Google Scholar · View at Scopus
  31. D. D. Sarbassov, D. A. Guertin, S. M. Ali, and D. M. Sabatini, “Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex,” Science (New York, New York), vol. 307, no. 5712, pp. 1098–1101, 2005. View at Publisher · View at Google Scholar · View at Scopus
  32. A. Toker, “Akt signaling: a damaging interaction makes good,” Trends in Biochemical Sciences, vol. 33, no. 8, pp. 356–359, 2008. View at Publisher · View at Google Scholar · View at Scopus
  33. D. A. Cross, D. R. Alessi, J. R. Vandenheede, H. E. McDowell, H. S. Hundal, and P. Cohen, “The inhibition of glycogen synthase kinase-3 by insulin or insulin-like growth factor 1 in the rat skeletal muscle cell line L6 is blocked by wortmannin, but not by rapamycin: evidence that wortmannin blocks activation of the mitogen-activated protein kinase pathway in L6 cells between Ras and Raf,” The Biochemical Journal, vol. 303, Part 1, pp. 21–26, 1994. View at Google Scholar
  34. U. A. White and J. M. Stephens, “Transcriptional factors that promote formation of white adipose tissue,” Molecular and Cellular Endocrinology, vol. 318, no. 1-2, pp. 10–14, 2010. View at Publisher · View at Google Scholar · View at Scopus
  35. J. Nakae, T. Kitamura, Y. Kitamura, W. H. Biggs 3rd, K. C. Arden, and D. Accili, “The forkhead transcription factor Foxo1 regulates adipocyte differentiation,” Developmental Cell, vol. 4, no. 1, pp. 119–129, 2003. View at Google Scholar
  36. C. E. Lowe, S. O'Rahilly, and J. J. Rochford, “Adipogenesis at a glance,” Journal of Cell Science, vol. 124, Part 16, pp. 2681–2686, 2011. View at Publisher · View at Google Scholar · View at Scopus
  37. D. Bai, L. Ueno, and P. K. Vogt, “Akt-mediated regulation of NFkappaB and the essentialness of NFkappaB for the oncogenicity of PI3K and Akt,” International Journal of Cancer, vol. 125, no. 12, pp. 2863–2870, 2009. View at Publisher · View at Google Scholar · View at Scopus
  38. S. Boura-Halfon and Y. Zick, “Serine kinases of insulin receptor substrate proteins,” Vitamins and Hormones, vol. 80, pp. 313–349, 2009. View at Publisher · View at Google Scholar · View at Scopus
  39. Y. Zick, “Uncoupling insulin signalling by serine/threonine phosphorylation: a molecular basis for insulin resistance,” Biochemical Society Transactions, vol. 32, Part 5, pp. 812–816, 2004. View at Publisher · View at Google Scholar · View at Scopus
  40. S. Boura-Halfon and Y. Zick, “Phosphorylation of IRS proteins, insulin action, and insulin resistance,” American Journal of Physiology Endocrinology and Metabolism, vol. 296, no. 4, pp. E581–E591, 2009. View at Publisher · View at Google Scholar · View at Scopus
  41. T. U. Demidova and E. N. Erokhina, “Effect of thiazolidinediones on insulin resistance and cardiovascular risk factors in type 2 diabetes,” Obesity and Metabolism (Russian), vol. 5, no. 2, pp. 2–5, 2008. View at Google Scholar
  42. R. B. Prasad and L. Groop, “Genetics of type 2 diabetes-pitfalls and possibilities,” Genes, vol. 6, no. 1, pp. 87–123, 2015. View at Publisher · View at Google Scholar · View at Scopus
  43. A. R. Saltiel, “New therapeutic approaches for the treatment of obesity,” Science Translational Medicine, vol. 8, no. 323, article 323rv2, 2016. View at Publisher · View at Google Scholar · View at Scopus
  44. J. P. Bastard, M. Maachi, C. Lagathu et al., “Recent advances in the relationship between obesity, inflammation, and insulin resistance,” European Cytokine Network, vol. 17, no. 1, pp. 4–12, 2006. View at Google Scholar
  45. L. D'Ignazio, D. Bandarra, and S. Rocha, “NF-kappaB and HIF crosstalk in immune responses,” The FEBS Journal, vol. 283, no. 3, pp. 413–424, 2016. View at Publisher · View at Google Scholar · View at Scopus
  46. P. S. Patel, E. D. Buras, and A. Balasubramanyam, “The role of the immune system in obesity and insulin resistance,” Journal of Obesity, vol. 2013, Article ID 616193, 9 pages, 2013. View at Publisher · View at Google Scholar · View at Scopus
  47. S. E. Shoelson, J. Lee, and A. B. Goldfine, “Inflammation and insulin resistance,” The Journal of Clinical Investigation, vol. 116, no. 7, pp. 1793–1801, 2006. View at Publisher · View at Google Scholar · View at Scopus
  48. C. N. Lumeng, S. M. Deyoung, and A. R. Saltiel, “Macrophages block insulin action in adipocytes by altering expression of signaling and glucose transport proteins,” American Journal of Physiology Endocrinology and Metabolism, vol. 292, no. 1, pp. E166–E174, 2007. View at Publisher · View at Google Scholar · View at Scopus
  49. S. M. Reilly and A. R. Saltiel, “Obesity: a complex role for adipose tissue macrophages,” Nature Reviews Endocrinology, vol. 10, no. 4, pp. 193-194, 2014. View at Publisher · View at Google Scholar · View at Scopus
  50. T. Suganami and Y. Ogawa, “Adipose tissue macrophages: their role in adipose tissue remodeling,” Journal of Leukocyte Biology, vol. 88, no. 1, pp. 33–39, 2010. View at Publisher · View at Google Scholar · View at Scopus
  51. J. I. Odegaard and A. Chawla, “Pleiotropic actions of insulin resistance and inflammation in metabolic homeostasis,” Science (New York, New York), vol. 339, no. 6116, pp. 172–177, 2013. View at Publisher · View at Google Scholar · View at Scopus
  52. I. S. Stafeev, M. Y. Menshikov, Z. I. Tsokolaeva, M. V. Shestakova, and Y. V. Parfyonova, “Molecular mechanisms of latent inflammation in metabolic syndrome. Possible role of sirtuins and peroxisome proliferator-activated receptor type gamma,” Biochemistry Biokhimiia, vol. 80, no. 10, pp. 1217–1226, 2015. View at Publisher · View at Google Scholar · View at Scopus
  53. L. Boutens and R. Stienstra, “Adipose tissue macrophages: going off track during obesity,” Diabetologia, vol. 59, no. 5, pp. 879–894, 2016. View at Publisher · View at Google Scholar · View at Scopus
  54. D. E. Lackey and J. M. Olefsky, “Regulation of metabolism by the innate immune system,” Nature Reviews Endocrinology, vol. 12, no. 1, pp. 15–28, 2016. View at Publisher · View at Google Scholar · View at Scopus
  55. A. Oeckinghaus, M. S. Hayden, and S. Ghosh, “Crosstalk in NF-kappaB signaling pathways,” Nature Immunology, vol. 12, no. 8, pp. 695–708, 2011. View at Publisher · View at Google Scholar · View at Scopus
  56. H. Hacker and M. Karin, “Regulation and function of IKK and IKK-related kinases,” Science’s STKE: Signal Transduction Knowledge Environment, vol. 2006, no. 357, article re13, 2006. View at Publisher · View at Google Scholar · View at Scopus
  57. M. H. Porter, A. Cutchins, J. B. Fine, Y. Bai, and M. DiGirolamo, “Effects of TNF-alpha on glucose metabolism and lipolysis in adipose tissue and isolated fat-cell preparations,” The Journal of Laboratory and Clinical Medicine, vol. 139, no. 3, pp. 140–146, 2002. View at Google Scholar
  58. J. Napetschnig and H. Wu, “Molecular basis of NF-kappaB signaling,” Annual Review of Biophysics, vol. 42, pp. 443–468, 2013. View at Publisher · View at Google Scholar · View at Scopus
  59. J. Hirosumi, G. Tuncman, L. Chang et al., “A central role for JNK in obesity and insulin resistance,” Nature, vol. 420, no. 6913, pp. 333–336, 2002. View at Publisher · View at Google Scholar · View at Scopus
  60. V. Aguirre, T. Uchida, L. Yenush, R. Davis, and M. F. White, “The c-Jun NH(2)-terminal kinase promotes insulin resistance during association with insulin receptor substrate-1 and phosphorylation of Ser(307),” The Journal of Biological Chemistry, vol. 275, no. 12, pp. 9047–9054, 2000. View at Google Scholar
  61. G. Solinas and M. Karin, “JNK1 and IKKbeta: molecular links between obesity and metabolic dysfunction,” FASEB Journal: Official Publication of the Federation of American Societies for Experimental Biology, vol. 24, no. 8, pp. 2596–2611, 2010. View at Publisher · View at Google Scholar · View at Scopus
  62. G. Solinas and B. Becattini, “JNK at the crossroad of obesity, insulin resistance, and cell stress response,” Molecular Metabolism, vol. 6, no. 2, pp. 174–184, 2017. View at Publisher · View at Google Scholar
  63. M. S. Han, D. Y. Jung, C. Morel et al., “JNK expression by macrophages promotes obesity-induced insulin resistance and inflammation,” Science (New York, New York), vol. 339, no. 6116, pp. 218–222, 2013. View at Publisher · View at Google Scholar · View at Scopus
  64. A. Bertola, T. Ciucci, D. Rousseau et al., “Identification of adipose tissue dendritic cells correlated with obesity-associated insulin-resistance and inducing Th17 responses in mice and patients,” Diabetes, vol. 61, no. 9, pp. 2238–2247, 2012. View at Publisher · View at Google Scholar · View at Scopus
  65. T. McLaughlin, L. F. Liu, C. Lamendola et al., “T-cell profile in adipose tissue is associated with insulin resistance and systemic inflammation in humans,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 34, no. 12, pp. 2637–2643, 2014. View at Publisher · View at Google Scholar · View at Scopus
  66. K. W. Cho, B. F. Zamarron, L. A. Muir et al., “Adipose tissue dendritic cells are independent contributors to obesity-induced inflammation and insulin resistance,” Journal of Immunology (Baltimore, Maryland : 1950), vol. 197, no. 9, pp. 3650–3661, 2016. View at Publisher · View at Google Scholar · View at Scopus
  67. Y. Kawano, J. Nakae, N. Watanabe et al., “Loss of Pdk1-Foxo1 signaling in myeloid cells predisposes to adipose tissue inflammation and insulin resistance,” Diabetes, vol. 61, no. 8, pp. 1935–1948, 2012. View at Publisher · View at Google Scholar · View at Scopus
  68. S. Mitchell, J. Vargas, and A. Hoffmann, “Signaling via the NF-kB system,” Wiley Interdisciplinary Reviews Systems Biology and Medicine, vol. 8, no. 3, pp. 227–241, 2016. View at Publisher · View at Google Scholar · View at Scopus
  69. G. Bonizzi and M. Karin, “The two NF-kappaB activation pathways and their role in innate and adaptive immunity,” Trends in Immunology, vol. 25, no. 6, pp. 280–288, 2004. View at Publisher · View at Google Scholar · View at Scopus
  70. T. Lawrence, M. Bebien, G. Y. Liu, V. Nizet, and M. Karin, “IKK[alpha] limits macrophage NF-[kappa]B activation and contributes to the resolution of inflammation,” Nature, vol. 434, no. 7037, pp. 1138–1143, 2005. View at Publisher · View at Google Scholar · View at Scopus
  71. D. Cai, M. Yuan, D. F. Frantz et al., “Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB,” Nature Medicine, vol. 11, no. 2, pp. 183–190, 2005. View at Publisher · View at Google Scholar · View at Scopus
  72. M. C. Arkan, A. L. Hevener, F. R. Greten et al., “IKK-beta links inflammation to obesity-induced insulin resistance,” Nature Medicine, vol. 11, no. 2, pp. 191–198, 2005. View at Publisher · View at Google Scholar · View at Scopus
  73. Z. Gao, D. Hwang, F. Bataille et al., “Serine phosphorylation of insulin receptor substrate 1 by inhibitor kappa B kinase complex,” The Journal of Biological Chemistry, vol. 277, no. 50, pp. 48115–48121, 2002. View at Publisher · View at Google Scholar · View at Scopus
  74. Y. Nakamori, M. Emoto, N. Fukuda et al., “Myosin motor Myo1c and its receptor NEMO/IKK-gamma promote TNF-alpha-induced serine307 phosphorylation of IRS-1,” The Journal of Cell Biology, vol. 173, no. 5, pp. 665–671, 2006. View at Publisher · View at Google Scholar · View at Scopus
  75. Q. Li, Q. Lu, J. Y. Hwang et al., “IKK1-deficient mice exhibit abnormal development of skin and skeleton,” Genes & Development, vol. 13, no. 10, pp. 1322–1328, 1999. View at Google Scholar
  76. O. Nidai Ozes, L. D. Mayo, J. A. Gustin, S. R. Pfeffer, L. M. Pfeffer, and D. B. Donner, “NF-[kappa]B activation by tumour necrosis factor requires the Akt serine-threonine kinase,” Nature, vol. 401, no. 6748, pp. 82–85, 1999. View at Publisher · View at Google Scholar · View at Scopus
  77. M. Delhase, N. Li, and M. Karin, “Kinase regulation in inflammatory response,” Nature, vol. 406, no. 6794, pp. 367-368, 2000. View at Publisher · View at Google Scholar · View at Scopus
  78. J. A. Gustin, O. N. Ozes, H. Akca et al., “Cell type-specific expression of the IkappaB kinases determines the significance of phosphatidylinositol 3-kinase/Akt signaling to NF-kappa B activation,” The Journal of Biological Chemistry, vol. 279, no. 3, pp. 1615–1620, 2004. View at Publisher · View at Google Scholar · View at Scopus
  79. J. A. Romashkova and S. S. Makarov, “NF-kappaB is a target of AKT in anti-apoptotic PDGF signalling,” Nature, vol. 401, no. 6748, pp. 86–90, 1999. View at Publisher · View at Google Scholar · View at Scopus
  80. N. Sizemore, S. Leung, and G. R. Stark, “Activation of phosphatidylinositol 3-kinase in response to interleukin-1 leads to phosphorylation and activation of the NF-kappaB p65/RelA subunit,” Molecular and Cellular Biology, vol. 19, no. 7, pp. 4798–4805, 1999. View at Google Scholar
  81. M. Yang, R. L. He, J. L. Benovic, and R. D. Ye, “beta-Arrestin1 interacts with the G-protein subunits beta1gamma2 and promotes beta1gamma2-dependent Akt signalling for NF-kappaB activation,” The Biochemical Journal, vol. 417, no. 1, pp. 287–296, 2009. View at Publisher · View at Google Scholar · View at Scopus
  82. V. R. Babaev, L. Ding, Y. Zhang et al., “Macrophage IKKalpha deficiency suppresses Akt phosphorylation, reduces cell survival, and decreases early atherosclerosis,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 36, no. 4, pp. 598–607, 2016. View at Publisher · View at Google Scholar · View at Scopus
  83. H. C. Dan, M. J. Cooper, P. C. Cogswell, J. A. Duncan, J. P. Ting, and A. S. Baldwin, “Akt-dependent regulation of NF-{kappa}B is controlled by mTOR and raptor in association with IKK,” Genes & Development, vol. 22, no. 11, pp. 1490–1500, 2008. View at Publisher · View at Google Scholar · View at Scopus
  84. Y. Xu, E. Lai, J. Liu et al., “IKK interacts with rictor and regulates mTORC2,” Cellular Signalling, vol. 25, no. 11, pp. 2239–2245, 2013. View at Publisher · View at Google Scholar · View at Scopus
  85. S.-H. Chiang, M. Bazuine, C. N. Lumeng et al., “The protein kinase IKKε regulates energy expenditure, insulin sensitivity and chronic inflammation in obese mice,” Cell, vol. 138, no. 5, pp. 961–975, 2009. View at Publisher · View at Google Scholar · View at Scopus
  86. S. M. Reilly, S.-H. Chiang, S. J. Decker et al., “An inhibitor of the protein kinases TBK1/IKKε improves obesity-related metabolic dysfunctions,” Nature Medicine, vol. 19, no. 3, pp. 313–321, 2013. View at Publisher · View at Google Scholar · View at Scopus
  87. T. Tamura, H. Yanai, D. Savitsky, and T. Taniguchi, “The IRF family transcription factors in immunity and oncogenesis,” Annual Review of Immunology, vol. 26, pp. 535–584, 2008. View at Publisher · View at Google Scholar · View at Scopus
  88. T. Shimada, T. Kawai, K. Takeda et al., “IKK-i, a novel lipopolysaccharide-inducible kinase that is related to IkappaB kinases,” International Immunology, vol. 11, no. 8, pp. 1357–1362, 1999. View at Google Scholar
  89. F. Bertrand, C. Philippe, P. J. Antoine et al., “Insulin activates nuclear factor kappa B in mammalian cells through a Raf-1-mediated pathway,” The Journal of Biological Chemistry, vol. 270, no. 41, pp. 24435–24441, 1995. View at Google Scholar
  90. I. Golovchenko, M. L. Goalstone, P. Watson, M. Brownlee, and B. Draznin, “Hyperinsulinemia enhances transcriptional activity of nuclear factor-kappaB induced by angiotensin II, hyperglycemia, and advanced glycosylation end products in vascular smooth muscle cells,” Circulation Research, vol. 87, no. 9, pp. 746–752, 2000. View at Google Scholar
  91. B. Dummler and B. A. Hemmings, “Physiological roles of PKB/Akt isoforms in development and disease,” Biochemical Society Transactions, vol. 35, Part 2, pp. 231–235, 2007. View at Publisher · View at Google Scholar · View at Scopus
  92. M. J. Lallena, M. T. Diaz-Meco, G. Bren, C. V. Paya, and J. Moscat, “Activation of IkappaB kinase beta by protein kinase C isoforms,” Molecular and Cellular Biology, vol. 19, no. 3, pp. 2180–2188, 1999. View at Google Scholar
  93. G. S. Hotamisligil, N. S. Shargill, and B. M. Spiegelman, “Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance,” Science (New York, New York), vol. 259, no. 5091, pp. 87–91, 1993. View at Google Scholar
  94. F. Ofei, S. Hurel, J. Newkirk, M. Sopwith, and R. Taylor, “Effects of an engineered human anti-TNF-alpha antibody (CDP571) on insulin sensitivity and glycemic control in patients with NIDDM,” Diabetes, vol. 45, no. 7, pp. 881–885, 1996. View at Google Scholar
  95. H. Dominguez, H. Storgaard, C. Rask-Madsen et al., “Metabolic and vascular effects of tumor necrosis factor-alpha blockade with etanercept in obese patients with type 2 diabetes,” Journal of Vascular Research, vol. 42, no. 6, pp. 517–525, 2005. View at Publisher · View at Google Scholar · View at Scopus
  96. L. E. Bernstein, J. Berry, S. Kim, B. Canavan, and S. K. Grinspoon, “Effects of etanercept in patients with the metabolic syndrome,” Archives of Internal Medicine, vol. 166, no. 8, pp. 902–908, 2006. View at Publisher · View at Google Scholar · View at Scopus
  97. T. L. Stanley, M. V. Zanni, S. Johnsen et al., “TNF-alpha antagonism with etanercept decreases glucose and increases the proportion of high molecular weight adiponectin in obese subjects with features of the metabolic syndrome,” The Journal of Clinical Endocrinology and Metabolism, vol. 96, no. 1, pp. E146–E150, 2011. View at Publisher · View at Google Scholar · View at Scopus
  98. M. Y. Donath, “Targeting inflammation in the treatment of type 2 diabetes: time to start,” Nature Reviews Drug Discovery, vol. 13, no. 6, pp. 465–476, 2014. View at Publisher · View at Google Scholar · View at Scopus
  99. M. Yuan, N. Konstantopoulos, J. Lee et al., “Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkbeta,” Science (New York, New York), vol. 293, no. 5535, pp. 1673–1677, 2001. View at Publisher · View at Google Scholar · View at Scopus
  100. E. Faghihimani, A. Aminorroaya, H. Rezvanian, P. Adibi, F. Ismail-Beigi, and M. Amini, “Salsalate improves glycemic control in patients with newly diagnosed type 2 diabetes,” Acta Diabetologica, vol. 50, no. 4, pp. 537–543, 2013. View at Publisher · View at Google Scholar · View at Scopus
  101. A. B. Goldfine, P. R. Conlin, F. Halperin et al., “A randomised trial of salsalate for insulin resistance and cardiovascular risk factors in persons with abnormal glucose tolerance,” Diabetologia, vol. 56, no. 4, pp. 714–723, 2013. View at Publisher · View at Google Scholar · View at Scopus
  102. A. B. Goldfine, V. Fonseca, K. A. Jablonski et al., “Salicylate (salsalate) in patients with type 2 diabetes: a randomized trial,” Annals of Internal Medicine, vol. 159, no. 1, pp. 1–12, 2013. View at Publisher · View at Google Scholar · View at Scopus
  103. C. M. Larsen, M. Faulenbach, A. Vaag, J. A. Ehses, M. Y. Donath, and T. Mandrup-Poulsen, “Sustained effects of interleukin-1 receptor antagonist treatment in type 2 diabetes,” Diabetes Care, vol. 32, no. 9, pp. 1663–1668, 2009. View at Publisher · View at Google Scholar · View at Scopus
  104. C. M. Larsen, M. Faulenbach, A. Vaag et al., “Interleukin-1-receptor antagonist in type 2 diabetes mellitus,” The New England Journal of Medicine, vol. 356, no. 15, pp. 1517–1526, 2007. View at Publisher · View at Google Scholar · View at Scopus
  105. J. Hensen, C. P. Howard, V. Walter, and T. Thuren, “Impact of interleukin-1beta antibody (canakinumab) on glycaemic indicators in patients with type 2 diabetes mellitus: results of secondary endpoints from a randomized, placebo-controlled trial,” Diabetes & Metabolism, vol. 39, no. 6, pp. 524–531, 2013. View at Publisher · View at Google Scholar · View at Scopus
  106. S. P. Weisberg, D. Hunter, R. Huber et al., “CCR2 modulates inflammatory and metabolic effects of high-fat feeding,” The Journal of Clinical Investigation, vol. 116, no. 1, pp. 115–124, 2006. View at Publisher · View at Google Scholar · View at Scopus
  107. M. C. Haigis and D. A. Sinclair, “Mammalian sirtuins: biological insights and disease relevance,” Annual Review of Pathology, vol. 5, pp. 253–295, 2010. View at Publisher · View at Google Scholar · View at Scopus
  108. Y. Imai, A. D. Dobrian, J. R. Weaver et al., “Interaction between cytokines and inflammatory cells in islet dysfunction, insulin resistance and vascular disease,” Diabetes, Obesity & Metabolism, vol. 15, Supplement 3, pp. 117–129, 2013. View at Publisher · View at Google Scholar · View at Scopus
  109. N. Esser, N. Paquot, and A. J. Scheen, “Anti-inflammatory agents to treat or prevent type 2 diabetes, metabolic syndrome and cardiovascular disease,” Expert Opinion on Investigational Drugs, vol. 24, no. 3, pp. 283–307, 2015. View at Google Scholar
  110. S. E. Shoelson, J. Lee, and M. Yuan, “Inflammation and the IKK beta/I kappa B/NF-kappa B axis in obesity- and diet-induced insulin resistance,” International Journal of Obesity and Related Metabolic Disorders: Journal of the International Association for the Study of Obesity, vol. 27, Supplement 3, pp. S49–S52, 2003. View at Publisher · View at Google Scholar · View at Scopus